For common outcomes there was similar efficacy between PDE-5 inhibitors
Background There are no r and omised and properly blinded trials directly comparing one PDE-5 inhibitor with another in a normal home setting .
Valid indirect comparisons with a common comparator must examine equivalent doses , similar duration , similar population s , with the same outcomes reported in the same way .
Efficacy and safety of sildenafil citrate (Viagra) in black and Hispanic American men.
The objective of this study was to assess the efficacy and safety of sildenafil citrate ( Viagra ) in black American and Hispanic American men with erectile dysfunction ( ED ) of broad-spectrum etiology . A total of 246 black American and 197 Hispanic American men were r and omized to sildenafil ( 50 mg , adjustable to 25 mg or 100 mg , depending on efficacy and tolerability ; n = 124 and n = 99 , respectively ) or matching placebo ( n = 122 and n = 98 , respectively ) . After 6 weeks , patients were given the option of switching to the other blinded treatment for the following 6 weeks . The 12 weeks of double-blind treatment were followed by 12 weeks of open-label extension . Despite differences in prevalence of hypertension , diabetes mellitus , hyperlipidemia , and use of concomitant antihypertensive agents between the 2 study groups , sildenafil was efficacious and well tolerated . After 6 weeks , scores for questions 3 and 4 from the International Index of Erectile Function ( IIEF ) were significantly higher among sildenafil-treated black and Hispanic patients than in placebo-treated patients . In addition , compared with placebo , a significantly larger proportion of sildenafil patients reported improved erections and improved ability to have sexual intercourse . When efficacy results were stratified by ED severity or number of risk factors , scores for IIEF questions 3 and 4 were lower in men with severe ED versus mild-to-moderate ED . Similarly , the percentage of patients reporting improved erections decreased with ED severity and number of risk factors . The proportion of patients switching to the other treatment after 6 weeks was significantly higher in the placebo group ( 71 % to 85 % ) than in the sildenafil group ( 27 % to 28 % ) . The most common adverse events included headache and vasodilation , which were mild to moderate in nature and were comparable between groups . These data demonstrate that despite differences in prevalence rates of comorbidities , efficacy and safety of sildenafil is maintained across different ethnic groups
For common outcomes there was similar efficacy between PDE-5 inhibitors
Background There are no r and omised and properly blinded trials directly comparing one PDE-5 inhibitor with another in a normal home setting .
Valid indirect comparisons with a common comparator must examine equivalent doses , similar duration , similar population s , with the same outcomes reported in the same way .